{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:57:15Z","timestamp":1791568635447,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ijtb.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T21:11:39Z","timestamp":1575580299000},"page":"520-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Adverse drug reactions in tuberculosis and management"],"prefix":"10.1016","volume":"66","author":[{"given":"Rajendra","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2019.11.005_bib1","series-title":"Global Tuberculosis Report 2018","year":"2018"},{"key":"10.1016\/j.ijtb.2019.11.005_bib2","series-title":"Requirements for Adverse Reaction Reporting","year":"1975"},{"key":"10.1016\/j.ijtb.2019.11.005_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line anti-tuberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ijtb.2019.11.005_bib4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.rmed.2006.01.014","article-title":"Side effects due to primary anti-tuberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis","volume":"10","author":"G\u00fclbay","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib5","first-page":"143","article-title":"Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs","volume":"62","author":"Tan","year":"2007","journal-title":"Med J Malays"},{"key":"10.1016\/j.ijtb.2019.11.005_bib6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijtb.2019.11.005_bib7","series-title":"Brasil. Minist\u00e9rio da Sa\u00fade. Funda\u00e7\u00e3o Nacional de Sa\u00fade. Centro de Refer\u00eancia Professor H\u00e9lio Fraga; Sociedade Brasileira de Pneumologia e Tisiologia. Controle da tuberculose: uma proposta de integra\u00e7\u00e3o ensino-servi\u00e7o","year":"2002"},{"key":"10.1016\/j.ijtb.2019.11.005_bib8","doi-asserted-by":"crossref","first-page":"s80","DOI":"10.1016\/j.cegh.2015.10.005","article-title":"Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis","volume":"3","author":"Singh","year":"2015","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.ijtb.2019.11.005_bib9","first-page":"868","article-title":"Adverse drug reactions associated with first-line anti-tuberculosis drug regimens","volume":"11","author":"Marra","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"issue":"s62","key":"10.1016\/j.ijtb.2019.11.005_bib10","first-page":"PA2700","article-title":"Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse (RTB) and newly diagnosed tuberculosis (NDTB)","volume":"52","author":"Butov","year":"2018","journal-title":"ERJ"},{"key":"10.1016\/j.ijtb.2019.11.005_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/1117-1936.171023","article-title":"Side effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerian's: a controlled clinical study","volume":"9","author":"Dosumu","year":"2002","journal-title":"Niger Post Grad Med J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib12","first-page":"219","article-title":"Controlled trial 6-month and 8-month regimen in the treatment of pulmonary tuberculosis. 1st report","volume":"118","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1590\/S1806-37132010000500016","article-title":"Anti-tuberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs","volume":"36","author":"Arbex","year":"2010","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1590\/S1806-37132008001200010","article-title":"Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of S\u00e3o Paulo, Brazil","volume":"34","author":"Vieira","year":"2008","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.ijtb.2019.11.005_bib16","first-page":"119","article-title":"Clinical trial of six month and four month regimen of chemotherapy in the TB of pulmonary tuberculosis. 1st report","volume":"579","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib17","series-title":"Fully intermittent dosing with drugs for treating tuberculosis in adults","author":"Mwandumba","year":"2005"},{"key":"10.1016\/j.ijtb.2019.11.005_bib18","unstructured":"Prasad R, Singh A, Gupta N, Giridhar BH. Epidemiology of adverse drug reaction with second line drugs among patients treated for multi-drug resistant tuberculosis. Eur J Biomed Pharm Sci; 2:553-561."},{"key":"10.1016\/j.ijtb.2019.11.005_bib19","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","article-title":"Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Wu","year":"2016","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.ijtb.2019.11.005_bib20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/jac\/dkx107","article-title":"Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis","volume":"72","author":"Schnippel","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijtb.2019.11.005_bib21","first-page":"648","article-title":"Occurrence of serious adverse effects in patients receiving community-based therapy for MDR-TB","volume":"5","author":"Furin","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib22","first-page":"1027","article-title":"Adverse events in the treatment of MDR-TB: results from the DOTS-Plus initiative","volume":"9","author":"Nathanson","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib23","first-page":"1314","article-title":"Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib24","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/MJT.0b013e3181c0806d","article-title":"Adverse effects of MDR-TB treatment with a standardized regimen: a report from Iran","volume":"18","author":"Baghaei","year":"2011","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.ijtb.2019.11.005_bib25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5588\/ijtld.11.0574","article-title":"Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort","volume":"167","author":"Carroll","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib26","first-page":"29","article-title":"Agra study of short course chemotherapy in pulmonary tuberculous patients","volume":"29","author":"Mehrotra","year":"1982","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.18203\/2349-3933.ijam20171512","article-title":"Impact of adverse drug reaction of first line anti - tuberculous drugs on treatment outcome of tuberculosis under revised national tuberculosis control programme","volume":"4","author":"Dedun","year":"2017","journal-title":"Int J Adv Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/2225-6482.184913","article-title":"Adverse drug reaction monitoring through active surveillance of anti-tubercular therapy in an urban tertiary care center","volume":"3","author":"Naser","year":"2016","journal-title":"Community Acquir Infect"},{"key":"10.1016\/j.ijtb.2019.11.005_bib29","first-page":"292","article-title":"Comparing the daily versus the intermittent regimens of the anti-tubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients","volume":"7","author":"Mandal","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.ijtb.2019.11.005_bib30","first-page":"976","article-title":"Seven-year DOTS-Plus pilot experience in India: results, constraints and issues","volume":"13","author":"Singla","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib31","first-page":"529","article-title":"Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India","volume":"133","author":"Joseph","year":"2011","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijtb.2019.11.005_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028066","article-title":"Ambulatory MDR-TB treatment outcomes in A cohort of HIV-infected patients in A slum setting in Mumbai, India","volume":"6","author":"Isaakidis","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2019.11.005_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040781","article-title":"Adverse events among HIV\/MDR-TB Co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India","volume":"7","author":"Isaakidis","year":"2012","journal-title":"PLoS One"},{"issue":"S57","key":"10.1016\/j.ijtb.2019.11.005_bib34","first-page":"P2820","article-title":"Adverse drug reactions to second line anti tuberculosis drugs: a prospective study in Mumbai, India","volume":"42","author":"Natarajan","year":"2013","journal-title":"ERJ"},{"key":"10.1016\/j.ijtb.2019.11.005_bib35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0970-2113.217569","article-title":"Adverse drug reactions and treatment outcome analysis of DOTS plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study","volume":"34","author":"Dela","year":"2017","journal-title":"Lung India"},{"key":"10.1016\/j.ijtb.2019.11.005_bib36","first-page":"181","article-title":"Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multi drug resistant pulmonary tuberculosis patients","volume":"48","author":"Prasad","year":"2006","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"10.1016\/j.ijtb.2019.11.005_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijtb.2016.01.031","article-title":"Adverse drug reaction in the treatment of multi drug resistant tuberculosis","volume":"63","author":"Prasad","year":"2016","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib38","first-page":"1","article-title":"Adverse reactions to first-line anti-tuberculous agents in hospitalised patients: pattern, causality, severity and risk factors","volume":"4","author":"Shinde","year":"2013","journal-title":"Indian J Med Specialities"},{"key":"10.1016\/j.ijtb.2019.11.005_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065037","article-title":"Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study","volume":"8","author":"Lv","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2019.11.005_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0377-1237(06)80155-3","article-title":"Risk factors of hepatotoxicity during anti-tuberculosis treatment","volume":"62","author":"Anand","year":"2006","journal-title":"MJAFI (Med J Armed Forces India)"},{"key":"10.1016\/j.ijtb.2019.11.005_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0041-3879(86)90003-6","article-title":"Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide","volume":"67","author":"Parthasarathy","year":"1986","journal-title":"Tubercle"},{"key":"10.1016\/j.ijtb.2019.11.005_bib42","first-page":"107","article-title":"Rifampicin and hepatic toxicity","volume":"30","author":"Purohit","year":"1983","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American thoracic society\/centers for disease control and prevention\/infectious diseases society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Hepatitis with isoniazid and rifampicin \u2013 a meta-analysis","volume":"99","author":"Steele","year":"1971","journal-title":"Chest"},{"key":"10.1016\/j.ijtb.2019.11.005_bib45","first-page":"963","article-title":"Isoniazid, rifampicin and hepatotoxicity","volume":"133","author":"Gangadharan","year":"1986","journal-title":"Am J Respir Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from anti-tuberculous drugs: a case control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.ijtb.2019.11.005_bib47","first-page":"73","article-title":"Predisposing factors in hepatitis induced by anti-tuberculosis regimens containing isoniazid, rifampicin and pyrazinamide: a case control study","volume":"9","author":"Prasad","year":"2006","journal-title":"JIMI"},{"key":"10.1016\/j.ijtb.2019.11.005_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MJT.0b013e31818f9eae","article-title":"Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to anti-tuberculous agents in new tuberculosis cases","volume":"17","author":"Baghaei","year":"2010","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.ijtb.2019.11.005_bib49","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with Rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib50","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/hep.1840210407","article-title":"Deleterious influence of pyrazinamide on the outcome of patients with fulminant or sub-fulminant liver failure during anti-tuberculous treatment including isoniazid","volume":"21","author":"Durand","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.ijtb.2019.11.005_bib51","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/hep.23534","article-title":"Anti-tuberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome","volume":"51","author":"Kumar","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ijtb.2019.11.005_bib52","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0149-2918(00)80053-3","article-title":"The safety profile of the fluoroquinolones","volume":"22","author":"Bertino","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijtb.2019.11.005_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0041-3879(68)90017-2","article-title":"A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association","volume":"49","year":"1968","journal-title":"Tubercle"},{"key":"10.1016\/j.ijtb.2019.11.005_bib54","first-page":"1","article-title":"Hepatic complications of anti- tuberculous therapy","volume":"44","author":"Rossouw","year":"1975","journal-title":"QJM"},{"key":"10.1016\/j.ijtb.2019.11.005_bib55","series-title":"Treatment of Drug-Resistant TB with New and Re-purposed Medications: A Field Guide","year":"2018"},{"key":"10.1016\/j.ijtb.2019.11.005_bib56","first-page":"531","article-title":"A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokharan","volume":"58","author":"Chhetri","year":"2008","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib57","article-title":"Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment","volume":"1","author":"Koju","year":"2005","journal-title":"Kathmandu Univ J Sci Eng Technol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00003495-198223010-00003","article-title":"Adverse effects of anti-tuberculosis drugs","volume":"23","author":"Girling","year":"1982","journal-title":"Drugs"},{"key":"10.1016\/j.ijtb.2019.11.005_bib59","series-title":"Guidelines for the Management of Adverse Drug Effects of Anti-mycobacterial Agents","year":"1998"},{"key":"10.1016\/j.ijtb.2019.11.005_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/1817-1737.43083","article-title":"Isoniazid- and ethambutol- induced psychosis","volume":"3","author":"Prasad","year":"2008","journal-title":"Ann Thorac Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib61","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00000441-195701000-00011","article-title":"Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients","volume":"233","author":"Cohn","year":"1957","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijtb.2019.11.005_bib62","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/bmj.2.5047.743","article-title":"Psychosis due to isoniazid","volume":"28","author":"Jackson","year":"1957","journal-title":"Br Med J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03161033","article-title":"Evolving epidemiology of drug-induced seizures reported to a Poison control center system","volume":"3","author":"Thundiyil","year":"2007","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib64","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/11534340-000000000-00000","article-title":"Nervous system effects of anti-tuberculosis therapy","volume":"24","author":"Kass","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ijtb.2019.11.005_bib65","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archopht.1962.00960020566009","article-title":"Ocular manifestations of ethambutol","volume":"67","author":"Carr","year":"1962","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/jop.1997.13.473","article-title":"Reversibility of ethambutol optic neuropathy","volume":"13","author":"Tsai","year":"1997","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2019.11.005_bib67","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1749-6632.1966.tb45532.x","article-title":"The ocular toxicity of ethambutol and its relation to dose","volume":"135","author":"Leibold","year":"1966","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijtb.2019.11.005_bib68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/thx.41.10.737","article-title":"Ocular toxicity from ethambutol (editorial)","volume":"41","author":"Citron","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.ijtb.2019.11.005_bib69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/149.1.23","article-title":"Risk factors for the development of auditory toxicity in patients receiving aminoglycosides","volume":"149","author":"Moore","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib71","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/00206097509071734","article-title":"Ototoxicity in children caused by streptomycin","volume":"14","author":"Prrazic","year":"1975","journal-title":"Audiology"},{"key":"10.1016\/j.ijtb.2019.11.005_bib72","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM196410292711808","article-title":"Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy","volume":"271","author":"Robinson","year":"1964","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib73","first-page":"245","article-title":"Familial occurrence of drug induced hearing loss","volume":"127","author":"Johnsonbaugh","year":"1974","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.ijtb.2019.11.005_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0041-3879(83)90032-6","article-title":"Study of Chemotherapy regimens of 5 and 7 months duration and the role of corticosteroids in the treatment of Sputum-positive patients with pulmonary tuberculosis in South India","volume":"64","year":"1983","journal-title":"Tubercle"},{"key":"10.1016\/j.ijtb.2019.11.005_bib75","first-page":"598","article-title":"Isoniazid, para-aminosalicylic acid and streptomycin intolerance in 1,744 patients","volume":"90","author":"Berte","year":"1964","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.56.1.10","article-title":"Incidence of drug intolerance to anti-tuberculosis chemotherapy","volume":"56","author":"Neff","year":"1969","journal-title":"Dis Chest"},{"key":"10.1016\/j.ijtb.2019.11.005_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40360-019-0313-y","article-title":"Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study","volume":"20","author":"Shibeshi","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijtb.2019.04.007","article-title":"Second-line injectable induced ototoxicity in drug resistant tuberculosis: a systematic review of Indian studies","volume":"66","author":"Sarin","year":"2019","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib79","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2019.11.005_bib80","first-page":"94","article-title":"Rifampicin induced thrombocytopenia","volume":"54","author":"Garg","year":"2007","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib81","first-page":"171","article-title":"Rifampicin induced thrombocytopenia","volume":"36","author":"Prasad","year":"1989","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib82","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0041-3879(89)90053-6","article-title":"Ethambutol induced thrombocytopenia","volume":"70","author":"Prasad","year":"1989","journal-title":"Tubercle"},{"key":"10.1016\/j.ijtb.2019.11.005_bib83","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0253-7613.64495","article-title":"Pyrazinamide induced thrombocytopenia","volume":"42","author":"Kant","year":"2010","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.ijtb.2019.11.005_bib84","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib85","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.11622\/smedj.2013097","article-title":"Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricemia","volume":"54","author":"Gerdan","year":"2013","journal-title":"Singap Med J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib86","first-page":"575","article-title":"Renal function in gout. III. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid)","volume":"47","author":"Gutman","year":"1969","journal-title":"Am J Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJM197204062861407","article-title":"Hyperuricemia due to ethambutol","volume":"286","author":"Postlethwaite","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib88","first-page":"251","article-title":"Adverse drug reactions observed during DOTS","volume":"36","author":"Dhingra","year":"2004","journal-title":"J Commun Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4046\/trd.2017.80.2.143","article-title":"Current status of fluoroquinolone use for treatment of tuberculosis in a tertiary care hospital in Korea","volume":"80","author":"Kang","year":"2017","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.ijtb.2019.11.005_bib90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib91","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib92","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.47.3.1010-1016.2003","article-title":"Aminoglycoside nephrotoxicity: modelling, simulation, and control","volume":"47","author":"Rougier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2019.11.005_bib93","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"de Jager","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.11.005_bib94","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijtb.2019.11.005_bib95","series-title":"Chemotherapy of Tuberculosis, mycobacterium Avium Complex Disease and Leprosy. Goodman and Gilman's the Pharmacological Basis of the Therapeutics","first-page":"1559","author":"Tawanda","year":"2011"},{"key":"10.1016\/j.ijtb.2019.11.005_bib96","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00403-008-0895-5","article-title":"Drug-induced lupus erythematosus","volume":"301","author":"Vedove","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ijtb.2019.11.005_bib97","first-page":"1","article-title":"Exfoliative dermatitis secondary to ethambutol and pyrazinamide","volume":"9","author":"Garg","year":"2008","journal-title":"Internet J Pulm Med"},{"key":"10.1016\/j.ijtb.2019.11.005_bib98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.pneumo.2009.08.006","article-title":"Severe systemic lupus erythematosus induced by isoniazid [Article in French]","volume":"65","author":"Rakotoson","year":"2009","journal-title":"Rev Pneumol Clin"},{"key":"10.1016\/j.ijtb.2019.11.005_bib99","first-page":"90","article-title":"A UK-based resource to support the monitoring and safe use of anti-tuberculosis drugs and second-line treatment of multidrug-resistant tuberculosis","author":"Potter","year":"2015","journal-title":"TB Drug Monographs"},{"key":"10.1016\/j.ijtb.2019.11.005_bib100","doi-asserted-by":"crossref","first-page":"1701462","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.11.005_bib101","first-page":"51","article-title":"Isoniazid induced gynaecomastia: a case report","volume":"56","author":"Garg","year":"2009","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0970-2113.95343","article-title":"Isoniazid related gynaecomastia: description of a case and systematic review of literature","volume":"29","author":"Khan","year":"2012","journal-title":"Lung India"},{"key":"10.1016\/j.ijtb.2019.11.005_bib103","first-page":"254","article-title":"Anaphylactic shock due to streptomycin sulphate","volume":"82","author":"Prasad","year":"1989","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.ijtb.2019.11.005_bib104","series-title":"A Practical Handbook on the Pharmacovigilance of Medicines Used in the Treatment of Tuberculosis. Enhancing the Safety of the TB Patient","year":"2012"},{"key":"10.1016\/j.ijtb.2019.11.005_bib105","series-title":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1. Bethesda","year":"2017"},{"key":"10.1016\/j.ijtb.2019.11.005_bib106","series-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","year":"2019"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570719304378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570719304378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:58:45Z","timestamp":1758081525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570719304378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0019570719304378"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2019.11.005","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions in tuberculosis and management","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Tuberculosis Association of India.","name":"copyright","label":"Copyright"}]}}